JP2024109657A5 - - Google Patents

Download PDF

Info

Publication number
JP2024109657A5
JP2024109657A5 JP2024076622A JP2024076622A JP2024109657A5 JP 2024109657 A5 JP2024109657 A5 JP 2024109657A5 JP 2024076622 A JP2024076622 A JP 2024076622A JP 2024076622 A JP2024076622 A JP 2024076622A JP 2024109657 A5 JP2024109657 A5 JP 2024109657A5
Authority
JP
Japan
Prior art keywords
sequence
transgene
promoter
clr
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024076622A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024109657A (ja
Filing date
Publication date
Priority claimed from PCT/US2018/050288 external-priority patent/WO2019051424A2/en
Application filed filed Critical
Publication of JP2024109657A publication Critical patent/JP2024109657A/ja
Publication of JP2024109657A5 publication Critical patent/JP2024109657A5/ja
Pending legal-status Critical Current

Links

JP2024076622A 2017-09-08 2024-05-09 キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法 Pending JP2024109657A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762556310P 2017-09-08 2017-09-08
US62/556,310 2017-09-08
PCT/US2018/050288 WO2019051424A2 (en) 2017-09-08 2018-09-10 COMPOSITIONS AND METHODS FOR CONDITIONAL GENE EXPRESSION MEDIATED BY A CHIMERIC LIGAND RECEPTOR (CLR)
JP2020513604A JP2020532987A (ja) 2017-09-08 2018-09-10 キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020513604A Division JP2020532987A (ja) 2017-09-08 2018-09-10 キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法

Publications (2)

Publication Number Publication Date
JP2024109657A JP2024109657A (ja) 2024-08-14
JP2024109657A5 true JP2024109657A5 (enExample) 2024-10-25

Family

ID=64270934

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020513604A Pending JP2020532987A (ja) 2017-09-08 2018-09-10 キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法
JP2024076622A Pending JP2024109657A (ja) 2017-09-08 2024-05-09 キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020513604A Pending JP2020532987A (ja) 2017-09-08 2018-09-10 キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法

Country Status (7)

Country Link
US (3) US12385061B2 (enExample)
EP (1) EP3679145A2 (enExample)
JP (2) JP2020532987A (enExample)
CN (1) CN111727256A (enExample)
AU (2) AU2018329741B2 (enExample)
CA (1) CA3072777A1 (enExample)
WO (1) WO2019051424A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12202856B2 (en) 2016-05-19 2025-01-21 The General Hospital Corporation Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
JP2020532987A (ja) 2017-09-08 2020-11-19 ポセイダ セラピューティクス，インコーポレイティド キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
CA3121247A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment
JP7711945B2 (ja) 2019-04-30 2025-07-23 センティ バイオサイエンシズ インコーポレイテッド キメラ受容体及びその使用方法
MX2021013218A (es) * 2019-05-01 2021-12-10 Pact Pharma Inc Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2.
JP7715640B2 (ja) * 2019-05-03 2025-07-30 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 異染性白質ジストロフィーの治療に有用な組成物
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
EP3753566A1 (en) * 2019-06-21 2020-12-23 Medizinische Hochschule Hannover All-in one viral vector for car and therapeutic effector molecule
EP4010361A4 (en) * 2019-08-06 2023-08-09 Children's Medical Center Corporation METHODS AND COMPOSITIONS FOR RESTORING MICROGLIA
WO2021046243A2 (en) 2019-09-03 2021-03-11 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
BR112022010460A2 (pt) * 2019-12-02 2022-09-06 Lg Chemical Ltd Fatores secretores de proteína derivada de células de cho e vetores de expressão compreendendo os mesmos
KR102937659B1 (ko) 2020-02-19 2026-03-10 우시 바이올로직스 아일랜드 리미티드 강화된 발현 시스템 및 그 사용방법
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
WO2021207526A1 (en) 2020-04-09 2021-10-14 The Regents Of The University Of California Humanized notch receptors with hinge domain
US20230167464A1 (en) * 2020-04-27 2023-06-01 The Trustees Of The University Of Pennsylvania Compositions and methods for reducing nuclease expression and off-target activity using a promoter with low transcriptional activity
WO2021234662A1 (en) * 2020-05-21 2021-11-25 Crispr Therapeutics Ag Genetically engineered car t cells that secrete interleukin-12 and therapeutic uses thereof
TW202220677A (zh) * 2020-07-31 2022-06-01 日商中外製藥股份有限公司 含有表現嵌合受體之細胞的醫藥組成物
WO2022226375A1 (en) * 2021-04-23 2022-10-27 Locanabio, Inc. Tissue-targeted modified aav capsids and methods of use thereof
EP4082560B1 (en) * 2021-04-27 2025-02-26 Academia Sinica Prap1 polypeptide for use in treating hypertriglyceridemia
CN117915930A (zh) * 2021-04-28 2024-04-19 总医院公司 与其受体IL-2Rβ结合的IL2以及成孔蛋白作为增强免疫细胞活性的平台
WO2022241029A1 (en) 2021-05-11 2022-11-17 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
EP4373845A4 (en) * 2021-07-23 2025-06-25 The Children's Medical Center Corporation Zinc finger ccch-type containing 14 (zc3h14) mutants and methods of use
JP2024531910A (ja) * 2021-08-04 2024-09-03 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト Ｌａｔ活性化キメラ抗原受容体ｔ細胞及びその使用方法
CN114940974A (zh) * 2021-09-28 2022-08-26 宁波熙宁检测技术有限公司 4-1bb报告基因293t稳转细胞株构建和应用
WO2023109911A1 (en) * 2021-12-15 2023-06-22 National Institute Of Biological Sciences, Beijing Microglia having car and use thereof
CN115216492B (zh) * 2022-06-29 2023-05-30 浙江欧赛思生物科技有限公司 一种小鼠原发神经胶质瘤模型的制备方法及其应用
GB202219568D0 (en) * 2022-12-22 2023-02-08 Autolus Ltd Chimeric antigen receptor
WO2025070635A1 (ja) * 2023-09-27 2025-04-03 味の素株式会社 免疫細胞培養用培地

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309989A (en) 1976-02-09 1982-01-12 The Curators Of The University Of Missouri Topical application of medication by ultrasound with coupling agent
GB2097032B (en) 1981-04-22 1984-09-19 Teron International Urban Dev A combined ceiling air and services distribution system mechanical chasse and structural roof member
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4766067A (en) 1985-05-31 1988-08-23 President And Fellows Of Harvard College Gene amplification
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4795699A (en) 1987-01-14 1989-01-03 President And Fellows Of Harvard College T7 DNA polymerase
US4921794A (en) 1987-01-14 1990-05-01 President And Fellows Of Harvard College T7 DNA polymerase
US4939666A (en) 1987-09-02 1990-07-03 Genex Corporation Incremental macromolecule construction methods
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5091310A (en) 1988-09-23 1992-02-25 Cetus Corporation Structure-independent dna amplification by the polymerase chain reaction
US5066584A (en) 1988-09-23 1991-11-19 Cetus Corporation Methods for generating single stranded dna by the polymerase chain reaction
US5142033A (en) 1988-09-23 1992-08-25 Hoffmann-La Roche Inc. Structure-independent DNA amplification by the polymerase chain reaction
US4994370A (en) 1989-01-03 1991-02-19 The United States Of America As Represented By The Department Of Health And Human Services DNA amplification technique
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
ES2118066T3 (es) 1989-10-05 1998-09-16 Optein Inc Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2109945T3 (es) 1990-06-01 1998-02-01 Chiron Corp Composiciones y procedimientos para identificar moleculas biologicamente activas.
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5580734A (en) 1990-07-13 1996-12-03 Transkaryotic Therapies, Inc. Method of producing a physical map contigous DNA sequences
WO1992005258A1 (en) 1990-09-20 1992-04-02 La Trobe University Gene encoding barley enzyme
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
IE920562A1 (en) 1991-02-21 1992-08-26 Gilead Sciences Aptamer specific for biomolecules and method of making
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5643252A (en) 1992-10-28 1997-07-01 Venisect, Inc. Laser perforator
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5763733A (en) 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5549551A (en) 1994-12-22 1996-08-27 Advanced Cardiovascular Systems, Inc. Adjustable length balloon catheter
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
ATE248583T1 (de) 1997-09-29 2003-09-15 Nektar Therapeutics In dosierinhalatoren verwendbare, stabilisierte zubereitungen
JP2003135078A (ja) * 2001-07-26 2003-05-13 Japan Tobacco Inc Ｃ型肝炎ウイルスｎｓ５ａタンパク質の変異体、およびその利用
JP2007517491A (ja) * 2003-12-29 2007-07-05 株式会社東京大学Ｔｌｏ 免疫調節剤を同定する方法、免疫調節剤、およびこれらの使用法
WO2006133398A2 (en) 2005-06-08 2006-12-14 Invitrogen Corporation In vitro activated donor t-cells to promote transplant engraftment
US9228180B2 (en) 2007-07-04 2016-01-05 Max-Delbruck-Centrum Fur Molekulare Medizin Polypeptide variants of sleeping beauty transposase
WO2010126766A1 (en) 2009-04-30 2010-11-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
FR2952374B1 (fr) * 2009-11-06 2012-11-16 Univ Claude Bernard Lyon Production de facteur ix recombinant dans une lignee cellulaire hepatocytaire humaine
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
MX358827B (es) * 2011-09-27 2018-09-05 Janssen Biotech Inc Supercóntigos de proteína basados en repeticiones de fibronectina tipo iii con superficies de unión alternativas.
BR112014020325A2 (pt) * 2012-02-17 2017-08-08 Childrens Hospital Philadelphia composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos
EP3569253A1 (en) 2013-06-05 2019-11-20 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
DK3105335T3 (da) 2014-02-14 2020-01-13 Univ Texas Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf
US10927384B2 (en) 2014-04-09 2021-02-23 Dna Twopointo Inc. DNA vectors, transposons and transposases for eukaryotic genome modification
CN107810420B (zh) * 2015-06-25 2020-08-14 豪夫迈·罗氏有限公司 用于测定抗体或配体结合和功能的基于细胞的测定
EP4339287A3 (en) * 2015-07-31 2024-05-22 Regents Of The University Of Minnesota Modified cells and methods of therapy
GB201514875D0 (en) * 2015-08-20 2015-10-07 Autolus Ltd Receptor
WO2017133175A1 (en) * 2016-02-04 2017-08-10 Nanjing Legend Biotech Co., Ltd. Engineered mammalian cells for cancer therapy
JP2019506177A (ja) * 2016-02-26 2019-03-07 ポセイダ セラピューティクス， インコーポレイテッド トランスポゾン系および使用方法
WO2018073394A1 (en) * 2016-10-19 2018-04-26 Cellectis Cell death inducing chimeric antigen receptors
CA3063695A1 (en) 2017-05-17 2018-11-22 Seattle Children's Hospital (Dba Seattle Children's Research Institute Generating mammalian t cell activation inducible synthetic promoters (syn+pro) to improve t cell therapy
AU2018301667A1 (en) 2017-07-12 2020-02-06 Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud Foundation Methods and systems for conditionally regulating gene expression
JP2020532987A (ja) 2017-09-08 2020-11-19 ポセイダ セラピューティクス，インコーポレイティド キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法
CA3111384A1 (en) 2018-09-05 2020-03-12 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use

Similar Documents

Publication Publication Date Title
JP7822340B2 (ja) キメラ抗原受容体およびその使用
US20240228576A1 (en) Therapeutic agents
JP7474281B2 (ja) リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加
US20260078200A1 (en) Systems and methods for targeting cancer cells
Nolan et al. Bypassing immunization: optimized design of “designer T cells” against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA
JP2022523961A5 (enExample)
JP2020532987A5 (enExample)
JP2024023228A5 (enExample)
JP2025517479A (ja) Ｂｃｍａ－ｃｄ１９を標的とする二重特異性キメラ抗原受容体およびその用途
TWI922317B (zh) TGF-β受體及使用方法
KR102316091B1 (ko) Bcma를 표적으로 하는 키메라 항원 수용체 및 이의 용도
US20250250356A1 (en) Chimeric receptors targeting adgre2 and/or clec12a and uses thereof
JP2020512284A (ja) 免疫系調節組成物および方法
CN111542545A (zh) Cd38定向嵌合抗原受体构建体
JP2022547416A (ja) Ｂ細胞標的化並列ＣＡＲ（ｐＣＡＲ）治療的薬剤
US20230227575A1 (en) Engineered T Cells
WO2023093811A1 (zh) 分子开关调控型嵌合抗原受体细胞和抗体的组合及其应用
US20250368715A1 (en) Chimeric Antigen Receptor
US20230100000A1 (en) Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens
Rutkowski et al. Clr-a: a novel immune-related C-type lectin-like molecule exclusively expressed by mouse gut epithelium
WO2022115565A2 (en) Chimeric receptors and methods of use thereof
JP7391984B2 (ja) 低酸素調節プロモーター及びその応用
US20180201689A1 (en) Antibody Fusion Protein and Preparation Method and Use Thereof
JP4635255B2 (ja) 抗体医薬
WO2024233287A1 (en) Viral vectors for cell therapy